PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

Inclusion Criteria:

• Male or female participants ≥18 years of age (≥12 years of age for Treatmentresistant primary Minimal Change Disease (TR-pMCD)) on the day of signing informedconsent/assent (Visit 1)

• Body Mass Index (BMI) of ≤40 kg/m2 at screening visit (Visit 1)

• Weight of ≥40 kg at screening

• Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 (chronic kidneydisease (CKD) EPI formula based on serum cystatin C) at screening visit

• For adult participants (≥18); ≥25 mL/min/1.73 m2 (CKD-EPI formula based onserum cystatin C) at the screening visit

• For adolescent participants (<18); ≥25 mL/min/1.73 m2 (chronic kidey diseaseunder 25 years (CKiD U25) formula using height and serum cystatin C) at thescreening visit

• Seated blood pressure (mean of 3 values) systolic blood pressure (SBP) ≤160 mmHg (adult participants ≥18) or SBP ≤140 mmHg (participants <18) at the screening visit (Visit 1). A participant with a documented history of white coat hypertension may beincluded as long as the participant is considered medically stable by theinvestigator and "true" blood pressure can be considered to be ≤160 mmHg (adultparticipants ≥18) or ≤140 mmHg (adolescent participants <18)

• Participants should be treated with angiotensin converting enzyme (ACE) inhibitorsor angiotensin receptor blockers (ARBs), at a stable optimised dose for at least 8weeks prior to the screening visit (Visit 1), with no plan to change the dose untilthe end of the randomised treatment period (i.e. end of trial (EoT), Week 20) unlessnot tolerated or indicated as per the discretion of the investigator

• If treated with (non-steroidal) mineralocorticoid receptor antagonist (MRA),endothelin receptor antagonists (ERA), glucagon-like peptide-1 (GLP-1) orSodium-glucose co-transporter-2 (SGLT2) inhibitors (SGLT2i), participants must be ona stable dose for at least 8 weeks prior to the screening visit (Visit 1),preferably with no plan to change the dose until the end of the randomiseddouble-blind treatment period (i.e. EoT, Week 20)

• Participants treated with oral immunosuppressive therapy except glucocorticoids (e.g. Calcineurin inhibitor(s) (CNI), mycophenolate mofetil/-sodium,cyclophosphamide) must be on a stable dose for at least 12 weeks prior to thescreening visit (Visit 1) with no plans to change their dose during the trialtreatment period

• Patients treated/to be treated with oral glucocorticoids have to be at a dose ≤10mg/d prednisolone or equivalent for ≥4 weeks prior to screening with no plan toincrease the dose during the treatment period.

Further inclusion criteria apply.

Exclusion Criteria:

• A history of organ transplantation or planned transplantation during the course ofthe study

• Use of intravenous immunosuppressive agents (e.g. cyclophosphamide, rituximab,obinutuzumab) in the past 6 months prior to screening visit (Visit 1)

• Participants in whom initiation of oral or IV immunosuppression is anticipatedduring the course of the trial

• Treatment with metformin or dofetilide (multidrug and toxin extrusion protein 1 (MATE1) substrates) within one week prior to randomisation visit (Visit 2) through 5days after the EoT visit

• Treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (CYP3A4/5) within one week or 5 half-lives (whichever is longer) prior torandomisation visit (Visit 2)

• Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) >3X the upper limitof normal (ULN) at screening visit (Visit 1)

• Clinically significant laboratory abnormalities or medical conditions which pose asafety risk for the participant or may interfere with the trial objectives in theinvestigator's opinion (except for renal function tests or deviation of clinicallaboratory values that are related to the podocytopathy in question) at screeningvisit

• QTc intervals (QTcF) greater than 450 ms in males or greater than 470 ms in females,or any other clinically relevant ECG findings (at the investigator's discretion) atscreening visit (Visit 1) Further exclusion criteria apply.